Human papillomavirus vaccine-recent results and future developments

Current Opinion in Pharmacology

Volumn 7, Issue 5, 2007, Pages 470-477

  Bonnez, William ^a,b  

^a UNIVERSITY OF ROCHESTER SCHOOL OF MEDICINE AND DENTISTRY   (United States)

^b UNIVERSITY OF ROCHESTER MEDICAL CENTER   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ALUMINUM HYDROXIDE; DIPHTHERIA PERTUSSIS TETANUS VACCINE; HEPATITIS B VACCINE; MENINGOCOCCUS VACCINE; NEUTRALIZING ANTIBODY; PLACEBO; WART VIRUS VACCINE;

BENIGN TUMOR; CLINICAL TRIAL; CONDYLOMA; DRUG EFFICACY; DRUG SAFETY; DRUG SYNTHESIS; DRUG WITHDRAWAL; FACIAL NERVE PARALYSIS; GASTROINTESTINAL INFECTION; GUILLAIN BARRE SYNDROME; HUMAN; HUMAN PAPILLOMAVIRUS TYPE 11; HUMAN PAPILLOMAVIRUS TYPE 16; HUMAN PAPILLOMAVIRUS TYPE 18; HUMAN PAPILLOMAVIRUS TYPE 6; HYPESTHESIA; INJECTION SITE ERYTHEMA; INJECTION SITE HYPERSENSITIVITY; INJECTION SITE PAIN; INJECTION SITE SWELLING; NONHUMAN; PRIORITY JOURNAL; REVIEW; UTERINE CERVIX CANCER; VIRUS LIKE AGENT;

HUMANS; PAPILLOMAVIRUS INFECTIONS; PAPILLOMAVIRUS VACCINES; TREATMENT OUTCOME;

EID: 35248829655     PISSN: 14714892     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.coph.2007.07.001     Document Type: Review

References (53)

1. Bernard H.U. The clinical importance of the nomenclature, evolution and taxonomy of human papillomaviruses. J Clin Virol 32 Suppl 1 (2005) S1-S6
2. Munoz N., Castellsague X., de Gonzalez A.B., and Gissmann L. Chapter 1: HPV in the etiology of human cancer. Vaccine 24S3 (2006) S1-S10
3. Brown D.R., Schroeder J.M., Bryan J.T., Stoler M.H., and Fife K.H. Detection of multiple human papillomavirus types in condylomata acuminata lesions from otherwise healthy and immunosuppressed patients. J Clin Microbiol 37 (1999) 3316-3322
4. Vandepapeliere P., Barrasso R., Meijer C.J., Walboomers J.M., Wettendorff M., Stanberry L.R., et al. Randomized controlled trial of an adjuvanted human papillomavirus (HPV) type 6 L2E7 vaccine: infection of external anogenital warts with multiple HPV types and failure of therapeutic vaccination. J Infect Dis 192 (2005) 2099-2107
5. Munoz N., Bosch F.X., Castellsague X., Diaz M., de Sanjose S., Hammouda D., et al. Against which human papillomavirus types shall we vaccinate and screen? The international perspective. Int J Cancer 111 (2004) 278-285
6. Parkin D.M., and Bray F. Chapter 2: the burden of HPV-related cancers. Vaccine 24 Suppl 3 (2006) S11-S25
7. D'Souza G., Kreimer A.R., Viscidi R., Pawlita M., Fakhry C., Koch W.M., et al. Case-control study of human papillomavirus and oropharyngeal cancer. N Engl J Med 356 (2007) 1944-1956
8. Clifford G., Franceschi S., Diaz M., Munoz N., and Villa L.L. Chapter 3: HPV type-distribution in women with and without cervical neoplastic diseases. Vaccine 24 Suppl 3 (2006) S26-S34
9. Parkin D.M. Global cancer statistics in the year 2000. Lancet Oncol 2 (2001) 533-543
10. Jemal A., Siegel R., Ward E., Murray T., Xu J., and Thun M.J. Cancer statistics, 2007. CA Cancer J Clin 57 (2007) 43-66
11. Chesson H.W., Blandford J.M., Gift T.L., Tao G., and Irwin K.L. The estimated direct medical cost of sexually transmitted diseases among American youth, 2000. Perspect Sex Reprod Health 36 (2004) 11-19
12. Rose R.C., Reichman R.C., and Bonnez W. Human papillomavirus type 11 (HPV-11) recombinant virus-like particles (VLPs) induce the formation of neutralizing antibodies and detect HPV-specific antibodies in human sera. J Gen Virol 75 (1994) 2075-2079
13. Breitburd F., and Coursaget P. Human papillomavirus vaccines. Semin Cancer Biol 9 (1999) 431-444
14. Harro C.D., Pang Y-YS, Roden R.B.S., Hildesheim A., Wang Z., Reynolds M.J., et al. Safety and immunogenicity trial in adult volunteers of a human papillomavirus 16 L1 virus-like particle vaccine. J Natl Cancer Inst 93 (2001) 284-292
15. Evans T.G., Bonnez W., Rose R.C., Koenig S., Demeter L., Suzich J.A., et al. A phase 1 study of a recombinant viruslike particle vaccine against human papillomavirus type 11 in healthy adult volunteers. J Infect Dis 183 (2001) 1485-1493. As with the study by Harro et al. [14], the Evans study examined different doses of HPV VLP antigen, and both demonstrated a vigorous antibody response with both binding and neutralizing functions. Evans et al. also showed that HPV-11 VLP stimulated T cells in a way that appeared not to be type-restricted. A cytokine expression pattern consistent with T helper cell type 1 and 2 responses was also noted.
16. Koutsky L.A., Ault K.A., Wheeler C.M., Brown D.R., Barr E., Alvarez F.B., et al. A controlled trial of a human papillomavirus type 16 vaccine. N Engl J Med 347 (2002) 1645-1651. This phase 2 controlled study of an HPV-16 L1 VLP vaccine was a milestone in the clinical development of the HPV vaccine. It demonstrated the complete efficacy of the vaccine in preventing cervical HPV-16 infection. It served to establish the model by which these types of vaccines are to be evaluated, by targeting a population of sexually active adolescent and young adults but with a low-to-moderate risk of being already HPV-infected. As expected, the study confirmed that immunization against HPV-16 did not necessarily prevent infections by other HPV types, as an equal number of subjects developed CIN not related to HPV-16. It also confirmed the low chance for transient infections to lead to CIN. None of the 6 vaccine recipients and 27 placebo recipients who were transiently positive for HPV-16 developed an HPV-16-related CIN. Although the six transient infections in the vaccine recipients might not have been true infections, and even if they were, this would give weight to the idea that below a certain viral exposure or load the body can clear an HPV infection.
17. Mao C., Koutsky L.A., Ault K.A., Wheeler C.M., Brown D.R., Wiley D.J., et al. Efficacy of human papillomavirus-16 vaccine to prevent cervical intraepithelial neoplasia: a randomized controlled trial. Obstet Gynecol 107 (2006) 18-27 [erratum appears in Obstet Gynecol. 2006 Jun;107(6):1425]
18. Harper D.M., Franco E.L., Wheeler C., Ferris D.G., Jenkins D., Schuind A., et al. Efficacy of a bivalent L1 virus-like particle vaccine in prevention of infection with human papillomavirus types 16 and 18 in young women: a randomised controlled trial. Lancet 364 (2004) 1757-1765
19. Harper D.M., Franco E.L., Wheeler C.M., Moscicki A.B., Romanowski B., Roteli-Martins C.M., et al. Sustained efficacy up to 4.5 years of a bivalent L1 virus-like particle vaccine against human papillomavirus types 16 and 18: follow-up from a randomised control trial. Lancet 367 (2006) 1247-1255. This publication is about an extension beyond 27 months of the study described in reference [18]. Originally, 1113 women were enrolled, and 776 were followed in the extension phase for up to 4.5 years, in the according-to-protocol cohort. Although, the primary endpoint was prevention not of disease or persistent infection but of HPV incident infection, both studies, though small in size, offer a very clear and convincing picture of the Cervarix's efficacy. The results are comparable to those reported with Gardasil, including when protocol violators (intention-to-treat analysis) were included. This study is also remarkable for showing that the vaccines also confer protection against HPV-45 (94.2% efficacy, 95% CI 63.3-99.9%) and HPV-31 (54.5%, 95% CI 11.5-77.7%) infections. The L1 gene DNA sequence of HPV-45 and HPV-31 are phylogenetically related to those of HPV-18 and HPV-16, respectively. At entry, the subjects were cytologically negative, seronegative for HPV-16 and HPV-18, and HPV DNA negative for 14 high-risk types, including types 16 and 18. This allowed the investigators to measure the impact of vaccination on the prevention of cervical disease caused by high-risk HPV types, not just types 16 and 18; it was 48.2% (95% CI 27.0-63.8%). The vaccine efficacy was still substantive, 39.8% (95% CI 20.9-54.4%) against cervical disease, irrespective of HPV DNA status. Simply interpreting these results as indicating a modest impact of the vaccine on cervical HPV disease is incomplete. First, as follow-up duration increases and as long as the vaccine remains effective, these efficacy figures will increase because placebo recipients will accrue disease at a faster rate than vaccinees (the same phenomenon has been documented with Gardasil see reference [23]). Second, although it is desirable to reduce screening cost to eliminate all grades of CIN, only the high grades, CIN 2 or 3 have the highest impact on the risk of invasive cancer. Although, the number of observations is too limited at this point to draw firm conclusions on the impact of the vaccine on these lesions, this study shows a vaccine efficacy of 67.1% against high-risk HPV type CIN2/3 and 73.3% against CIN2/3 independent of HPV DNA status.
20. Kang M., and Lagakos S.W. Evaluating the role of human papillomavirus vaccine in cervical cancer prevention. Stat Methods Med Res 13 (2004) 139-155
21. Garland S.M., Hernandez-Avila M., Wheeler C.M., Perez G., Harper D.M., Leodolter S., et al. Quadrivalent vaccine against human papillomavirus to prevent anogenital diseases. N Engl J Med 356 (2007) 1928-1943
22. Koutsky L.A. Quadrivalent vaccine against human papillomavirus to prevent high-grade cervical lesions. N Engl J Med 356 (2007) 1915-1927
23. Ault K.A. Effect of prophylactic human papillomavirus L1 virus-like-particle vaccine on risk of cervical intraepithelial neoplasia grade 2, grade 3, and adenocarcinoma in situ: a combined analysis of four randomised clinical trials. Lancet 369 (2007) 1861-1868
24. ••] presents the updated results, at 36 month of follow-up, of the main studies that led to the licensing of the first HPV VLP vaccine (Gardasil, Merck), which is directed at HPV types 6, 11, 16, and 18. The first two publications are devoted to Merck protocols 013 and 015, respectively. The last two present the combined results of these studies as well as those of two antecedents studies (protocols 005 and 007) to provide a more precise assessment of the vaccine efficacy. The first two publications address the vaccine safety in detail by analyzing data collected from almost 18 000 subjects.
25. Block S.L., Nolan T., Sattler C., Barr E., Giacoletti K.E., Marchant C.D., et al. Comparison of the immunogenicity and reactogenicity of a prophylactic quadrivalent human papillomavirus (types 6, 11, 16 and 18) L1 virus-like particle vaccine in male and female adolescents and young adult women. Pediatrics 118 (2006) 2135-2145
26. Reisinger K.S., Block S.L., Lazcano-Ponce E., Samakoses R., Esser M.T., Erick J., et al. Safety and persistent immunogenicity of a quadrivalent human papillomavirus types 6, 11, 16, 18 L1 virus-like particle vaccine in preadolescents and adolescents: a randomized controlled trial. Pediatr Infect Dis J 26 (2007) 201-209
27. Pedersen C., Petaja T., Strauss G., Rumke H.C., Poder A., Richardus J.H., et al. Immunization of early adolescent females with human papillomavirus type 16 and 18 L1 virus-like particle vaccine containing AS04 adjuvant. J Adolesc Health 40 (2007) 564-571
28. Markowitz L.E., Dunne E.F., Saraiya M., Lawson H.W., Chesson H., Unger E.R., et al. Quadrivalent human papillomavirus vaccine: recommendations of the Advisory Committee on Immunization Practices (ACIP). MMWR Recomm Rep 56 (2007) 1-24. This reference offers the finalized recommendations of the ACIP for the use of the quadrivalent HPV vaccine. Anyone who wants to use the vaccine is invited to consult this document that covers some aspects of the immunization in a greater detail than this reviews allows. The site of the American Academy of Pediatrics (http://www.cispimmunize.org/) is also an excellent resource.
29. Advisory Committee on Immunization Practices, February 21-22, 2007, Atlanta, Georgia, Record of the Proceedings. www.cdc.gov/vaccines/recs/acip/downloads/acip_min_feb07.pdf.
30. Guillain-Barré syndrome (GBS) among persons who received meningococcal conjugate vaccine. In Centers for Disease Control and Prevention; 2007. http://www.cdc.gov/od/science/iso/concerns/gbsfactsheet.htm.
31. Prevention of human papillomavirus infection: provisional recommendations for immunization of females with quadrivalent human papillomavirus vaccine. In American Academy of Pediatrics; 2007. http://www.cispimmunize.org/ill/pdf/HPVprovisional.pdf.
32. Saslow D., Castle P.E., Cox J.T., Davey D.D., Einstein M.H., Ferris D.G., et al. American Cancer Society Guideline for human papillomavirus (HPV) vaccine use to prevent cervical cancer and its precursors. CA Cancer J Clin 57 (2007) 7-28
33. Sawaya G.F., and Smith-McCune K. HPV vaccination-more answers, more questions. N Engl J Med 356 (2007) 1991-1993
34. Schiffman M., Herrero R., Desalle R., Hildesheim A., Wacholder S., Rodriguez A.C., et al. The carcinogenicity of human papillomavirus types reflects viral evolution. Virology 337 (2005) 76-84
35. FDA Executive Summary-GARDASIL Licensing Action; 2006. www.fda.gov/cber/sba/hpvmer060806s.pdf.
36. Elbasha E.H., and Galvani A.P. Vaccination against multiple HPV types. Math Biosci 197 (2005) 88-117
37. Bonnez W., Harvey C., Rose R.C., and Reichman R.C. Use of HPV-11 viral particles in an ELISA to detect antibodies in humans with or without condylomata acuminata. Ninth International Papillomavirus Workshop. Heidelberg, FRG (1990) 153
38. Bonnez W., Greer C., DaRin C., Borkhuis C., Van Nest G., and Rose R.C. Correlation between ELISA and neutralizing activities of anti-HPV-6 L1 virus-like particles (VLP) rabbit antisera against HPV-11. 15th International Papillomavirus Workshop. Gold Coast, Queensland, Australia, December 1-5 (1996)
39. Touze A., Dupuy C., Mahe D., Sizaret P.Y., and Coursaget P. Production of recombinant virus-like particles from human papillomavirus types 6 and 11, and study of serological reactivities between HPV 6, 11, 16 and 45 by ELISA: implications for papillomavirus prevention and detection. FEMS Microbiol Lett 160 (1998) 111-118
40. Wang X.M., Cook J.C., Lee J.C., Jansen K.U., Christensen N.D., Ludmerer S.W., et al. Human papillomavirus type 6 virus-like particles present overlapping yet distinct conformational epitopes. J Gen Virol 84 (2003) 1493-1497
41. Combita A.L., Touze A., Bousarghin L., Christensen N.D., and Coursaget P. Identification of two cross-neutralizing linear epitopes within the L1 major capsid protein of human papillomaviruses. J Virol 76 (2002) 6480-6486
42. Smith J.F., Brownlow M.K., Brown M.J., Esser M.T., Ruiz W., and Brown D.R. Gardasil antibodies cross-neutralize pseudovirion infection of vaccine-related HPV types. 23rd International Papillomavirus Conference & Clinical Workshop. Prague, Czech Republic, September 1-7 (2006)
43. Villa L.L., Costa R.L., Petta C.A., Andrade R.P., Paavonen J., Iversen O.E., et al. High sustained efficacy of a prophylactic quadrivalent human papillomavirus types 6/11/16/18 L1 virus-like particle vaccine through 5 years of follow-up. Br J Cancer 95 (2006) 1459-1466
44. Dias D., Van Doren J., Schlottmann S., Kelly S., Puchalski D., Ruiz W., et al. Optimization and validation of a multiplexed luminex assay to quantify antibodies to neutralizing epitopes on human papillomaviruses 6, 11, 16 and 18. Clin Diagn, Lab Immunol 12 (2005) 959-969
45. Olsson S.E., Villa L.L., Costa R.L., Petta C.A., Andrade R.P., Malm C., et al. Induction of immune memory following administration of a prophylactic quadrivalent human papillomavirus (HPV) types 6/11/16/18 L1 virus-like particle (VLP) vaccine. Vaccine 25 (2007) 4931-4939
46. Giannini S.L., Hanon E., Moris P., Van Mechelen M., Morel S., Dessy F., et al. Enhanced humoral and memory B cellular immunity using HPV16/18 L1 VLP vaccine formulated with the MPL/aluminium salt combination (AS04) compared to aluminium salt only. Vaccine 24 (2006) 5937-5949
47. Hughes J.P., Garnett G.P., and Koutsky L. The theoretical population-level impact of a prophylactic human papilloma virus vaccine. Epidemiology 13 (2002) 631-639
48. Elbasha E.H., Dasbach E.J., and Insinga R.P. Model for assessing human papillomavirus vaccination strategies. Emerg Infect Dis 13 (2007) 28-41
49. Dasbach E.J., Elbasha E.H., and Insinga R.P. Mathematical models for predicting the epidemiologic and economic impact of vaccination against human papillomavirus infection and disease. Epidemiol Rev 28 (2006) 88-100
50. Li M., Cripe T.P., Estes P.A., Lyon M.K., Rose R.C., and Garcea R.L. Expression of the human papillomavirus type 11 L1 capsid protein in Escherichia coli: characterization of protein domains involved in DNA binding and capsid assembly. J Virol 71 (1997) 2988-2995
51. Chen X.S., Casini G., Harrison S.C., and Garcea R.L. Papillomavirus capsid protein expression in Escherichia coli: purification and assembly of HPV11 and HPV16 L1. J Mol Biol 307 (2001) 173-182
52. Kulasingam S.L., and Myers E.R. Potential health and economic impact of adding a human papillomavirus vaccine to screening programs. JAMA 290 (2003) 781-789
53. Freed G.L., and Derkay C.S. Prevention of recurrent respiratory papillomatosis: role of HPV vaccination. Int J Ped Otorhinolaryngol 70 (2006) 1799-1803